ANAPTYSBIO, INC. Public Float
ANAPTYSBIO, INC. (ANAB) had Public Float of $632.72 million as of 2025-12-31, per its 10-KT filed 2026-09-21.
Financial Statements › Notes › Cover Page
dei:EntityPublicFloat · last filed 2026-09-21
- 2025-12-31: Entity Public Float $632.72M.
- 2025-06-30: Entity Public Float $432.51M.
- 2024-06-30: Entity Public Float $487.84M.
- 2023-06-30: Entity Public Float $366.56M.
| Period end | Entity Public Float |
|---|---|
| 2025-12-31 | $632.72M 10-KT · filed 2026-09-21 |
| 2025-06-30 | $432.51M 10-K/A · filed 2026-04-28 |
| 2024-06-30 | $487.84M 10-K · filed 2025-02-27 |
| 2023-06-30 | $366.56M 10-K · filed 2024-03-11 |
| 2022-06-30 | $400.39M 10-K · filed 2023-03-01 |
| 2021-06-30 | $489.31M 10-K · filed 2022-03-07 |
| 2020-06-30 | $555.99M 10-K · filed 2021-02-25 |
| 2019-06-30 | $1.39B 10-K · filed 2020-03-02 |
| 2018-06-30 | $1.52B 10-K · filed 2019-02-28 |
| 2017-06-30 | $267.65M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |